Session » (1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1531

Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials

10:30AM-12:30PM: Abstract Number: 1542

Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial

10:30AM-12:30PM: Abstract Number: 1547

Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice

10:30AM-12:30PM: Abstract Number: 1548

Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice

10:30AM-12:30PM: Abstract Number: 1540

Association of Hypoalbuminemia with Serious Infections in Systemic Lupus Erythematosus Patients Receiving Dialysis

10:30AM-12:30PM: Abstract Number: 1533

Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US

10:30AM-12:30PM: Abstract Number: 1551

Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey

10:30AM-12:30PM: Abstract Number: 1518

Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature

10:30AM-12:30PM: Abstract Number: 1545

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study

10:30AM-12:30PM: Abstract Number: 1536

Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA

10:30AM-12:30PM: Abstract Number: 1523

Genetic architecture and translational insights for SLE progression from preclinical stages

10:30AM-12:30PM: Abstract Number: 1526

Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project

10:30AM-12:30PM: Abstract Number: 1524

Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1549

Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort

10:30AM-12:30PM: Abstract Number: 1535

INB-619 – A Novel Gamma-Delta (γδ) T cell Engager to Target B cells in Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 1528

Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1521

Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data

10:30AM-12:30PM: Abstract Number: 1537

Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease

10:30AM-12:30PM: Abstract Number: 1520

Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 1543

Low-Dose Aspirin Therapy in Patients with Type 2 Diabetes and Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study

10:30AM-12:30PM: Abstract Number: 1527

Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool

10:30AM-12:30PM: Abstract Number: 1522

Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database

10:30AM-12:30PM: Abstract Number: 1519

Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study

10:30AM-12:30PM: Abstract Number: 1532

Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1534

Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting

10:30AM-12:30PM: Abstract Number: 1550

Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program

10:30AM-12:30PM: Abstract Number: 1525

Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment

10:30AM-12:30PM: Abstract Number: 1538

Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277

10:30AM-12:30PM: Abstract Number: 1546

Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response

10:30AM-12:30PM: Abstract Number: 1517

The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters

10:30AM-12:30PM: Abstract Number: 1539

The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis

10:30AM-12:30PM: Abstract Number: 1530

The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1541

Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort

10:30AM-12:30PM: Abstract Number: 1552

Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study

10:30AM-12:30PM: Abstract Number: 1529

Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE

10:30AM-12:30PM: Abstract Number: 1544

Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].